BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 9220291)

  • 1. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
    Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
    Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
    J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule.
    Pazdur R; Lassere Y; Diaz-Canton E; Ho DH
    Cancer Invest; 1998; 16(3):145-51. PubMed ID: 9541627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of UFT plus leucovorin in colorectal cancer.
    Pazdur R
    Oncology; 1997; 54 Suppl 1():19-23. PubMed ID: 8978580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.
    Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
    Anticancer Drugs; 1996 Sep; 7(7):728-33. PubMed ID: 8949982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma.
    Mani S; Sciortino D; Samuels B; Arrietta R; Schilsky RL; Vokes EE; Benner S
    Invest New Drugs; 1999; 17(1):97-101. PubMed ID: 10555128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma.
    Mani S; Schiano T; Garcia JC; Ansari RH; Samuels B; Sciortino DF; Tembe S; Shulman KL; Baker A; Benner SE; Vokes EE
    Invest New Drugs; 1998-1999; 16(3):279-83. PubMed ID: 10360610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study.
    Mani S; Kugler JW; Sciortino DF; Garcia JC; Ansari RH; Humerickhouse R; Michelassi F; Posner MC; Shulman KL; Schilsky RL; List M; Vokes EE; Benner S
    Ann Oncol; 1998 Sep; 9(9):1035-7. PubMed ID: 9818081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
    Pazdur R
    Oncology (Williston Park); 1997 Sep; 11(9 Suppl 10):35-9. PubMed ID: 9348565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer.
    Childs HA; Spencer SA; Raben D; Bonner JA; Newsome J; Robert F
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):939-44. PubMed ID: 10863063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. UFT modulated with leucovorin in advanced colorectal cancer: Oncopaz experience.
    González Barón M; Feliu J; Garcia Girón C; Espinosa J; Martinez B; Blanco E; Crespo MC; Ordóñez A; Espinosa E; de Castro J; Juárez F; Colmenarejo A
    Oncology; 1997; 54 Suppl 1():24-9. PubMed ID: 8978581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.
    Saltz LB; Leichman CG; Young CW; Muggia FM; Conti JA; Spiess T; Jeffers S; Leichman LP
    Cancer; 1995 Feb; 75(3):782-5. PubMed ID: 7828128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
    Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
    Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I study of orally administered UFT plus l-leucovorin].
    Horikoshi N; Aiba K; Kanamaru R; Hasegawa K; Takeda S; Taguchi T; Niitani H; Furue H; Kurihara M; Ogawa M; Abe T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):531-9. PubMed ID: 9530359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.